Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205998 | 0.84 | HSP90AA1 (0.34) | KDM4EPDE9AMAP4K4HSP90AA1 | |
| SCHEMBL14250161 | 0.78 | — | — | |
| SCHEMBL30339210 | 0.78 | — | — | |
| SCHEMBL32667194 | 0.74 | OPRM1 (0.38) | KDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL28118056 | 0.74 | OPRM1 (0.38) | KDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL28197535 | 0.74 | MAP4K4 (0.40) | MAP4K4NAMPTHSP90AA1 | |
| SCHEMBL20995461 | 0.74 | CYP11B2 (0.44) | ALDH1A1PIM1MAP4K4NAMPTHSP90AA1 | |
| SCHEMBL24835711 | 0.74 | PIM1 (0.38) | PIM1DYRK1APIK3CDPIK3CA | |
| SCHEMBL3388644 | 0.73 | HSP90AA1 (0.39) | KDM4EMAP4K4HSP90AA1 | |
| SCHEMBL22334578 | 0.73 | PDE10A (0.33) | PIM1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720068-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| WO-2024245430-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB3, ERBB2 | KDM4E 1276/4885ALDH1A1 2000/4885HTT 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.